Erratum: Manganese-enhanced magnetic resonance imaging reveals increased DOI-induced brain activity in a mouse model of schizophrenia (Proceedings of the National Academy of Sciences of the United States of America (2014) 111 (E2492-E2500) DOI: 10.1073/pnas.1323287111);Manganese-enhanced magnetic resonance imaging reveals increased DOI-induced brain activity in a mouse model of schizophrenia

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 24, 2014, Pages 14307-14308

  Malkova, Natalia V ^a   Gallagher, Joseph J ^a   Yu, Collin Z ^b   Jacobs, Russell E ^a   Patterson, Paul H ^a  

^a California Institute of Technology   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Immediate early gene; MEMRI; Neurodevelopment; Polyinosinic:polycytidylic acid

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLOOXYGENASE 2; EARLY GROWTH RESPONSE FACTOR 1; KETANSERIN; MANGANESE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN FUNCTION; BRAIN REGION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORPUS STRIATUM; DOWNSTREAM PROCESSING; FEMALE; HALLUCINATION; HEAD TWITCH; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; THALAMUS; THALAMUS PARAFASCICULAR NUCLEUS;

IMMEDIATE EARLY GENE; MEMRI; NEURODEVELOPMENT; POLYINOSINIC:POLYCYTIDYLIC ACID;

AMPHETAMINES; ANIMALS; BEHAVIOR, ANIMAL; BRAIN MAPPING; BRAIN-DERIVED NEUROTROPHIC FACTOR; CONTRAST MEDIA; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; EARLY GROWTH RESPONSE PROTEIN 1; HALLUCINOGENS; KETANSERIN; LIGANDS; MAGNETIC RESONANCE IMAGING; MALE; MANGANESE; MICE; MICE, INBRED C57BL; NEURONS; POLY I-C; PREFRONTAL CORTEX; RECEPTOR, SEROTONIN, 5-HT2A; RISK FACTORS; SCHIZOPHRENIA;

EID: 84902590140     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1416478111     Document Type: Erratum

References (85)

1. Malkova NV, Yu CZ, Hsiao EY, Moore MJ, Patterson PH (2012) Maternal immune activation yields offspring displaying mouse versions of the three core symptoms of autism. Brain Behav Immun 26(4):607-616.
2. Meyer U, Feldon J, Dammann O (2011) Schizophrenia and autism: Both shared and disorder-specific pathogenesis via perinatal inflammation? Pediatr Res 69(5 Pt 2): 26R-33R.
3. Paparelli A, Di Forti M, Morrison PD, Murray RM (2011) Drug-induced psychosis: How to avoid star gazing in schizophrenia research by looking at more obvious sources of light. Front Behav Neurosci 5:1.
4. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9(17):3897-3902. (Pubitemid 29189323)
5. Turner WM, Tsuang MT (1990) Impact of substance abuse on the course and outcome of schizophrenia. Schizophr Bull 16(1):87-95. (Pubitemid 20110378)
6. Patterson PH (2009) Immune involvement in schizophrenia and autism: Etiology, pathology and animal models. Behav Brain Res 204(2):313-321.
7. Meyer U, Feldon J (2012) To poly(I:C) or not to poly(I:C): Advancing preclinical schizophrenia research through the use of prenatal immune activation models. Neuropharmacology 62(3):1308-1321.
8. Romero E, et al. (2007) Neurobehavioral and immunological consequences of prenatal immune activation in rats. Influence of antipsychotics. Neuropsychopharmacology 32(8): 1791-1804. (Pubitemid 47076375)
9. Lu H, et al. (2007) Cocaine-induced brain activation detected by dynamic manganese-enhanced magnetic resonance imaging (MEMRI). Proc Natl Acad Sci USA 104(7): 2489-2494. (Pubitemid 46391423)
10. Van der Linden A, Van Meir V, Tindemans I, Verhoye M, Balthazart J (2004) Applications of manganese-enhanced magnetic resonance imaging (MEMRI) to image brain plasticity in song birds. NMR Biomed 17(8):602-612. (Pubitemid 40124785)
11. Yu X, Wadghiri YZ, Sanes DH, Turnbull DH (2005) In vivo auditory brain mapping in mice with Mn-enhanced MRI. Nat Neurosci 8(7):961-968.
12. Yu X, et al. (2008) Statistical mapping of sound-evoked activity in the mouse auditory midbrain using Mn-enhanced MRI. Neuroimage 39(1):223-230. (Pubitemid 350102205)
13. Corne SJ, Pickering RW (1967) A possible correlation between drug-induced hallucinations in man and a behavioural response in mice. Psychopharmacology (Berl) 11(1): 65-78.
14. González-Maeso J, et al. (2007) Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53(3):439-452. (Pubitemid 46161267)
15. Nakagawasai O, et al. (2004) Monoamine oxidase and head-twitch response in mice. Mechanisms of alpha-methylated substrate derivatives. Neurotoxicology 25(1-2): 223-232. (Pubitemid 38044184)
16. Willins DL, Meltzer HY (1997) Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmacol Exp Ther 282(2):699-706. (Pubitemid 27340170)
17. González-Maeso J, et al. (2003) Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci 23(26):8836-8843. (Pubitemid 37210895)
18. Perles-Barbacaru TA, Procissi D, Demyanenko AV, Jacobs RE (2012) Quantitative pharmacologic MRI in mice. NMR Biomed 25(4):498-505.
19. McKune CM, Watts SW (2001) Characterization of the serotonin receptor mediating contraction in the mouse thoracic aorta and signal pathway coupling. J Pharmacol Exp Ther 297(1):88-95. (Pubitemid 32242566)
20. Nagatomo T, Rashid M, Abul Muntasir H, Komiyama T (2004) Functions of 5-HT2A receptor and its antagonists in the cardiovascular system. Pharmacol Ther 104(1): 59- 81.
21. Pautler RG, Koretsky AP (2002) Tracing odor-induced activation in the olfactory bulbs of mice using manganese-enhanced magnetic resonance imaging. Neuroimage 16(2): 441-448. (Pubitemid 34852459)
22. Silva AC, Lee JH, Aoki I, Koretsky AP (2004) Manganese-enhanced magnetic resonance imaging (MEMRI): Methodological and practical considerations. NMR Biomed 17(8): 532-543. (Pubitemid 40124779)
23. Zwingmann C, Leibfritz D, Hazell AS (2003) Energy metabolism in astrocytes and neurons treated with manganese: Relation among cell-specific energy failure, glucose metabolism, and intercellular trafficking using multinuclear NMR-spectroscopic analysis. J Cereb Blood Flow Metab 23(6):756-771. (Pubitemid 36713681)
24. Amargós-Bosch M, et al. (2004) Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex. Cereb Cortex 14(3):281-299. (Pubitemid 38252721)
25. Mackowiak M, et al. (2002) DOI, an agonist of 5-HT2A/2C serotonin receptor, alters the expression of cyclooxygenase-2 in the rat parietal cortex. J Physiol Pharmacol 53(3):395-407.
26. Angelucci F, Brenè S, Mathé AA (2005) BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry 10(4):345-352.
27. Vaidya VA, Marek GJ, Aghajanian GK, Duman RS (1997) 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci 17(8):2785-2795. (Pubitemid 27155012)
28. Muguruza C, et al. (2013) Dysregulated 5-HT(2A) receptor binding in postmortem frontal cortex of schizophrenic subjects. Eur Neuropsychopharmacol 23(8):852-864.
29. Benekareddy M, Goodfellow NM, Lambe EK, Vaidya VA (2010) Enhanced function of prefrontal serotonin 5-HT(2) receptors in a rat model of psychiatric vulnerability. J Neurosci 30(36):12138-12150.
30. 2 receptors in the adult offspring. J Neurosci 31(5): 1863-1872.
31. Holloway T, et al. (2013) Prenatal stress induces schizophrenia-like alterations of serotonin 2A and metabotropic glutamate 2 receptors in the adult offspring: Role of maternal immune system. J Neurosci 33(3):1088-1098.
32. Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003) Serotonin receptors: Their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27(7): 1159-1172. (Pubitemid 37464960)
33. Rasmussen H, et al. (2011) Serotonin2A receptor blockade and clinical effect in firstepisode schizophrenia patients treated with quetiapine. Psychopharmacology (Berl) 213(2-3):583-592.
34. Meltzer HY, Massey BW, Horiguchi M (2012) Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. Curr Pharm Biotechnol 13(8):1572-1586.
35. Benekareddy M, Vadodaria KC, Nair AR, Vaidya VA (2011) Postnatal serotonin type 2 receptor blockade prevents the emergence of anxiety behavior, dysregulated stressinduced immediate early gene responses, and specific transcriptional changes that arise following early life stress. Biol Psychiatry 70(11):1024-1032.
36. Trenk D, Mosler A, Kirch W, Meinertz T, Jähnchen E (1983) Pharmacokinetics and pharmacodynamics of the 5-HT2 receptor antagonist ketanserin in man. J Cardiovasc Pharmacol 5(6):1034-1039. (Pubitemid 14234351)
37. Dwivedi Y, Mondal AC, Payappagoudar GV, Rizavi HS (2005) Differential regulation of serotonin (5HT)2A receptor mRNA and protein levels after single and repeated stress in rat brain: Role in learned helplessness behavior. Neuropharmacology 48(2): 204-214. (Pubitemid 40208256)
38. Brown AS (2012) Epidemiologic studies of exposure to prenatal infection and risk of schizophrenia and autism. Dev Neurobiol 72(10):1272-1276.
39. Bitanihirwe BK, Peleg-Raibstein D, Mouttet F, Feldon J, Meyer U (2010) Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia. Neuropsychopharmacology 35(12):2462-2478.
40. Meyer U, Feldon J, Fatemi SH (2009) In-vivo rodent models for the experimental investigation of prenatal immune activation effects in neurodevelopmental brain disorders. Neurosci Biobehav Rev 33(7):1061-1079.
41. Shi L, Fatemi SH, Sidwell RW, Patterson PH (2003) Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J Neurosci 23(1): 297-302. (Pubitemid 36050430)
42. Smith SE, Li J, Garbett K, Mirnics K, Patterson PH (2007) Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 27(40):10695-10702. (Pubitemid 47535869)
43. Zuckerman L, Weiner I (2005) Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring. J Psychiatr Res 39(3):311-323. (Pubitemid 40255916)
44. Vardy MM, Kay SR (1983) LSD psychosis or LSD-induced schizophrenia? A multi-method inquiry. Arch Gen Psychiatry 40(8):877-883. (Pubitemid 13025221)
45. Quednow BB, Kometer M, Geyer MA, Vollenweider FX (2012) Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology 37(3):630-640.
46. Kometer M, Schmidt A, Jäncke L, Vollenweider FX (2013) Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. J Neurosci 33(25):10544-10551.
47. Farid M, Martinez ZA, Geyer MA, Swerdlow NR (2000) Regulation of sensorimotor gating of the startle reflex by serotonin 2A receptors. Ontogeny and strain differences. Neuropsychopharmacology 23(6):623-632.
48. Halberstadt AL, Geyer MA (2010) LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT(2A) receptor. Psychopharmacology (Berl) 208(2):179-189.
49. Hanks JB, González-Maeso J (2013) Animal models of serotonergic psychedelics. ACS Chem Neurosci 4(1):33-42.
50. Moreno JL, Sealfon SC, González-Maeso J (2009) Group II metabotropic glutamate receptors and schizophrenia. Cell Mol Life Sci 66(23):3777-3785.
51. Carhart-Harris RL, et al. (2012) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci USA 109(6):2138-2143.
52. Vollenweider FX, et al. (1997) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16(5):357-372. (Pubitemid 27211734)
53. Delgado MG, Bogousslavsky J (2013) ' Distorteidolias'-Fantastic perceptive distortion. A new, pure dorsomedial thalamic syndrome. Eur Neurol 70(1-2):6-9.
54. Boes APS, Caviness V, Fox M (2013) The neuroanatomy of peduncular hallucinosis: A case series and lesion overlap analysis. Neurology 80(Meeting Abstracts 1):S18.004.
55. Barch DM, Ceaser A (2012) Cognition in schizophrenia: Core psychological and neural mechanisms. Trends Cogn Sci 16(1):27-34.
56. Buchsbaum MS, Hazlett EA (1998) Positron emission tomography studies of abnormal glucose metabolism in schizophrenia. Schizophr Bull 24(3):343-364. (Pubitemid 28378221)
57. Sapara A, et al. (2007) Prefrontal cortex and insight in schizophrenia: A volumetric MRI study. Schizophr Res 89(1-3):22-34. (Pubitemid 44881313)
58. Abi-Dargham A (2007) Alterations of serotonin transmission in schizophrenia. Int Rev Neurobiol 78:133-164.
59. Iqbal N, van Praag HM (1995) The role of serotonin in schizophrenia. Eur Neuropsychopharmacol 5(Suppl):11-23. (Pubitemid 26022214)
60. Lambe EK, Fillman SG, Webster MJ, Shannon Weickert C (2011) Serotonin receptor expression in human prefrontal cortex: Balancing excitation and inhibition across postnatal development. PLoS ONE 6(7):e22799.
61. Puig MV (2011) Serotonergic modulation of the prefrontal cortex: From neurons to brain waves. Psychiatric Disorders-Worldwide Advances, ed Uehara T (InTech, Croatia), pp 3-22.
62. Hawrylycz MJ, et al. (2012) An anatomically comprehensive atlas of the adult human brain transcriptome. Nature 489(7416):391-399.
63. Fatemi SH, et al. (2002) Prenatal viral infection leads to pyramidal cell atrophy and macrocephaly in adulthood: Implications for genesis of autism and schizophrenia. Cell Mol Neurobiol 22(1):25-33. (Pubitemid 34579406)
64. Polesskaya OO, Aston C, Sokolov BP (2006) Allele C-specific methylation of the 5-HT2A receptor gene: Evidence for correlation with its expression and expression of DNA methylase DNMT1. J Neurosci Res 83(3):362-373. (Pubitemid 43184400)
65. Millan MJ, Marin P, Bockaert J, Mannoury la Cour C (2008) Signaling at G-protein-coupled serotonin receptors: Recent advances and future research directions. Trends Pharmacol Sci 29(9):454-464.
66. Weinstein H (2005) Hallucinogen actions on 5-HT receptors reveal distinct mechanisms of activation and signaling by G protein-coupled receptors. AAPS J 7(4): E871 - E884.
67. Garcia EE, Smith RL, Sanders-Bush E (2007) Role of G(q) protein in behavioral effects of the hallucinogenic drug 1-(2,5-dimethoxy-4-iodophenyl)-2- aminopropane. Neuropharmacology 52(8):1671-1677. (Pubitemid 46843142)
68. Lin XH, Kitamura N, Hashimoto T, Shirakawa O, Maeda K (1999) Opposite changes in phosphoinositide-specific phospholipase C immunoreactivity in the left prefrontal and superior temporal cortex of patients with chronic schizophrenia. Biol Psychiatry 46(12):1665-1671. (Pubitemid 30001609)
69. Udawela M, Scarr E, Hannan AJ, Thomas EA, Dean B (2011) Phospholipase C beta 1 expression in the dorsolateral prefrontal cortex from patients with schizophrenia at different stages of illness. Aust N Z J Psychiatry 45(2):140-147.
70. Lo Vasco VR, Cardinale G, Polonia P (2012) Deletion of PLCB1 gene in schizophrenia-affected patients. J Cell Mol Med 16(4):844-851.
71. Hollinger S, Hepler JR (2002) Cellular regulation of RGS proteins: Modulators and integrators of G protein signaling. Pharmacol Rev 54(3):527-559.
72. Mirnics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P (2001) Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry 6(3):293-301. (Pubitemid 32275674)
73. Grillet N, et al. (2005) Generation and characterization of Rgs4 mutant mice. Mol Cell Biol 25(10):4221-4228. (Pubitemid 40617667)
74. Lauterborn JC, et al. (1996) Differential effects of protein synthesis inhibition on the activity-dependent expression of BDNF transcripts: Evidence for immediate-early gene responses from specific promoters. J Neurosci 16(23):7428-7436. (Pubitemid 26389681)
75. Yermakova A, O'Banion MK (2000) Cyclooxygenases in the central nervous system: Implications for treatment of neurological disorders. Curr Pharm Des 6(17): 1755 - 1776.
76. Takahashi M, et al. (2000) Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry 5(3):293-300. (Pubitemid 30438405)
77. Tang B, Capitao C, Dean B, Thomas EA (2012) Differential age- and disease-related effects on the expression of genes related to the arachidonic acid signaling pathway in schizophrenia. Psychiatry Res 196(2-3):201-206.
78. Winter C, et al. (2009) Prenatal immune activation leads to multiple changes in basal neurotransmitter levels in the adult brain: Implications for brain disorders of neuro-developmental origin such as schizophrenia. Int J Neuropsychopharmacol 12(4): 513-524.
79. Ebdrup BH, Rasmussen H, Arnt J, Glenthøj B (2011) Serotonin 2A receptor antagonists for treatment of schizophrenia. Expert Opin Investig Drugs 20(9):1211-1223.
80. Gallagher JJ, et al. (2013) Altered reward circuitry in the norepinephrine transporter knockout mouse. PLoS ONE 8(3):e57597.
81. Gallagher JJ, Zhang X, Ziomek GJ, Jacobs RE, Bearer EL (2012) Deficits in axonal transport in hippocampal-based circuitry and the visual pathway in APP knock-out animals witnessed by manganese enhanced MRI. Neuroimage 60(3):1856-1866.
82. Hennig J, Nauerth A, Friedburg H (1986) RARE imaging: A fast imaging method for clinical MR. Magn Reson Med 3(6):823-833. (Pubitemid 17233280)
83. Woods RP, Grafton ST, Watson JD, Sicotte NL, Mazziotta JC (1998) Automated image registration: II. Intersubject validation of linear and nonlinear models. J Comput Assist Tomogr 22(1):153-165. (Pubitemid 28087338)
84. Friston KJ (2003) Statistical parametric mapping. Statistical Parametric Mapping: The Analysis of Functional Brain Images, eds Penny WD, Friston KJ, Ashburner JT, Kiebel SJ, Nichols TE (Academic, Burlington, MA), pp 10-31.
85. Pautler RG (2004) In vivo, trans-synaptic tract-tracing utilizing manganese-enhanced magnetic resonance imaging (MEMRI). NMR Biomed 17(8):595-601.